ArticleBiomedica : revista del Instituto Nacional de Salud2020
Candidemia in Colombia
Article in Biomedica : revista del Instituto Nacional de Salud, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Candidemia in Colombia: Species Distribution and Antifungal Susceptibility Profiles of Yeast Bloodstream Isolates from a Six-Year Multicentre Surveillance Study.Journal of fungi (Basel, Switzerland) · 2026Article
- Shift in Candidemia Epidemiology and Emerging Fluconazole Resistance inJournal of fungi (Basel, Switzerland) · 2026Article
- Candida species identified by MAL-DI-TOF and antifungal susceptibility in hospitalized patients with COVID-19 in Peru.Revista peruana de medicina experimental y salud publica · 2026Observational
- Neonatal Candidemia in Latin America: Trends, Resistance, and Prevention Strategies (2008-2025).Journal of fungi (Basel, Switzerland) · 2026Review
- Optimizing Antifungal Use Through Interdisciplinary Intervention in the Hematology Unit.Journal of fungi (Basel, Switzerland) · 2026Article
- Clinical and microbiological epidemiology of Candida infections in a high-complexity hospital in Tolima, Colombia (2014-2024).PloS one · 2026Observational
- Genomic epidemiology of Colombian resistantAntimicrobial agents and chemotherapy · 2025Article
- Changing Climate, ChangingJournal of fungi (Basel, Switzerland) · 2025Review
- Invasive Candidiasis in Contexts of Armed Conflict, High Violence, and Forced Displacement in Latin America and the Caribbean (2005-2025).Journal of fungi (Basel, Switzerland) · 2025Review
- Epidemiological characteristics of pediatric patients with invasive candidiasis in an intensive care unit in southwestern ColombiaBiomedica : revista del Instituto Nacional de Salud · 2025Observational
- Molecular Evaluation of the mRNA Expression of theJournal of fungi (Basel, Switzerland) · 2024Article
- Article
- Prevalence and Species Distribution ofJournal of fungi (Basel, Switzerland) · 2024Article
- Occurrence of pathogenic yeastF1000Research · 2024Article
- Study of Candidemia and its Antifungal Susceptibility Profile at the University Hospital of Montevideo, Uruguay.Mycopathologia · 2023Article
- Therapeutic Use of the Antimicrobial Peptide PNR20 to Resolve Disseminated Candidiasis in a Murine Model.Journal of fungi (Basel, Switzerland) · 2023Article
- Method validation for the quantification of fluconazole and its organic impurities in raw material using high-performance liquid chromatographyBiomedica : revista del Instituto Nacional de Salud · 2023Article
- Article
- Combining the Peptide RWQWRWQWR and an Ethanolic Extract ofJournal of fungi (Basel, Switzerland) · 2023Article
- In Vitro Antifungal Activity of Three Synthetic Peptides againstAntibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Colombia, especially in intensive care units, candidemia is a frequent cause of infection, accounting for 88% of fungal infections in hospitalized patients, with mortality ranging from 36% to 78%. Its incidence in Colombia is higher than that reported in developed countries and even higher than in other Latin American countries. First, the patient’s risk factors should be considered, and then clinical characteristics should be assessed. Finally, microbiological studies are recommended and if the evidence supports its use, molecular testing. In general, American, Latin American, and European guides place the echinocandins as the first-line treatment for candidemia and differ in the use of fluconazole based on evidence, disease severity, previous exposure to azoles, and prevalence of Candida non-albicans. Taking into account the high incidence of this disease in our setting, it should be looked for in patients with risk factors to start a prompt empirical anti-fungal treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.